SNS-062
98%
- Product Code: 109643
CAS:
1270014-40-8
| Molecular Weight: | 384.87 g./mol | Molecular Formula: | C₁₉H₂₁ClN₆O |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
SNS-062 is primarily investigated for its potential therapeutic applications in treating various forms of cancer. It functions as a kinase inhibitor, specifically targeting Bruton's tyrosine kinase (BTK), which plays a critical role in the survival and proliferation of certain cancer cells, particularly in hematologic malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, SNS-062 disrupts signaling pathways that promote tumor growth and survival, making it a promising candidate for targeted cancer therapy. Additionally, its application is being explored in cases where resistance to other BTK inhibitors has developed, offering a potential treatment option for patients with relapsed or refractory disease. Research is ongoing to evaluate its efficacy, safety, and potential use in combination with other anticancer agents.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿26,055.00 |
+
-
|
SNS-062
SNS-062 is primarily investigated for its potential therapeutic applications in treating various forms of cancer. It functions as a kinase inhibitor, specifically targeting Bruton's tyrosine kinase (BTK), which plays a critical role in the survival and proliferation of certain cancer cells, particularly in hematologic malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, SNS-062 disrupts signaling pathways that promote tumor growth and survival, making it a promising candidate for targeted cancer therapy. Additionally, its application is being explored in cases where resistance to other BTK inhibitors has developed, offering a potential treatment option for patients with relapsed or refractory disease. Research is ongoing to evaluate its efficacy, safety, and potential use in combination with other anticancer agents.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :